dc.creator | Ruiz Villaverde, Ricardo | es |
dc.creator | Domínguez Cruz, Javier | es |
dc.creator | Navarro Triviño, Francisco J. | es |
dc.creator | Galán Gutiérrez, Manuel | es |
dc.creator | Armario Hita, José Carlos | es |
dc.creator | Pereyra-Rodríguez, José-Juan | es |
dc.date.accessioned | 2023-06-22T13:34:29Z | |
dc.date.available | 2023-06-22T13:34:29Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Ruiz Villaverde, R., Domínguez Cruz, J., Navarro Triviño, F.J., Galán Gutiérrez, M., Armario Hita, J.C. y Pereyra-Rodríguez, J. (2022). Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders). Life, 12 (8), 1192. https://doi.org/10.3390/life12081192. | |
dc.identifier.issn | 2075-1729 | es |
dc.identifier.uri | https://hdl.handle.net/11441/147422 | |
dc.description.abstract | In this Special Issue entitled Atopic Dermatitis: New Perspectives, we have tried to collect
research of special interest related mainly to the incorporation of pathophysiological aspects
and therapeutic novelties in this regard.
Pereyra et al. [1] carry out a systematic review and network meta-analysis (NMA)
in which they carry out a short-term evaluation of the short-term efficacy and safety
of biological molecules and small molecules that have recently been incorporated into
our therapeutic arsenal. Upadacitinib and Abrocitinib are the drugs with the highest
efficacy, both in monotherapy and in association with TCS. However, they were also those
associated with the highest risk of adverse effects, showing monoclonal antibodies’ better
safety profile. | es |
dc.format | application/pdf | es |
dc.format.extent | 4 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI AG | es |
dc.relation.ispartof | Life, 12 (8), 1192. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Atopic dermatitis | es |
dc.title | Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders) | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.mdpi.com/2075-1729/12/8/1192 | es |
dc.identifier.doi | 10.3390/life12081192 | es |
dc.contributor.group | Universidad de Sevilla. CTS1088: Enfermedades Inmunomediadas. | es |
dc.journaltitle | Life | es |
dc.publication.volumen | 12 | es |
dc.publication.issue | 8 | es |
dc.publication.initialPage | 1192 | es |